CAPD and bone marrow cell-cell interaction abnormality in end stage renal disease.
In this research the early erythroid progenitor (BFU-E) growth has been observed in patients with chronic renal failure by studying in "in vitro" cultures the number of BFU-E developed per plate under various experimental conditions. Our results demonstrate that the BFU-E growth of uremic patients in the predialysis phase or on hemodialysis is suppressed both in basal conditions and with the addition of lympho-monocytes of normal subjects or CAPD patients to the "in vitro" cultures. In CAPD patients, on the contrary, the BFU-E growth appears near normal levels in basal conditions and is further more enhanced by adding the normal lympho-monocytes to the "in vitro" cultures. The above mentioned facts signify that in uremic patients both the abnormality of bone marrow and immunocompetent cells may be responsible for the suppressed BFU-E growth, while with CAPD the improvement of both systems allow a normalisation of erythropoiesis. Such a recovery with CAPD demonstrates the presence of an inhibitor material in uremia which is better depurated by this technique.
D000328:Adult; D001853:Bone Marrow / Q000276:immunology / Q000473:pathology; D001854:Bone Marrow Cells; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000032:analysis; D007676:Kidney Failure, Chronic / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D008264:Macrophages / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology; D010530:Peritoneal Dialysis; D010531:Peritoneal Dialysis, Continuous Ambulatory; D006435:Renal Dialysis; D013601:T-Lymphocytes / Q000276:immunology
D007376:Interleukin-2